Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Single-Arm Open-Label Study of GYNORYLAQ™-VLINIVAL™ Quantum-Entangled Personalized Neoantigen Peptide Vaccine (Seq⊗HLA⊗Immune→|ΨT⟩) in High-Risk/Recurrent Endometrial Carcinoma

NCT07316361 is registered in ClinicalTrials.gov with Biogenea Pharmaceuticals Ltd. as lead sponsor.

NCT NCT07316361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07316361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Single-Arm Open-Label Study of GYNORYLAQ™-VLINIVAL™ Quantum-Entangled Personalized Neoantigen Peptide Vaccine (Seq⊗HLA⊗Immune→|ΨT⟩) in High-Risk/Recurrent Endometrial Carcinoma
Lead sponsor
Biogenea Pharmaceuticals Ltd.
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
February 2, 2026
Completion date
December 2, 2031
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial carcinoma, endometrial carcinoma stage iii